South San Francisco, CA — January 24th, 2019 —
Genentech, a member of the Roche Group, today announced the appointment of Alexander Hardy to chief executive officer, effective March 1, 2019.
Hardy first joined Genentech in 2005, where he held several senior management positions, including leading patient access services and overseeing commercial operations for a range of therapeutic areas from HER2-positive cancer to influenza and neuroscience. In 2014, he became head of Asia Pacific for Roche Pharmaceuticals and is currently head of Global Product Strategy. Hardy succeeds Bill Anderson, who was recently appointed chief executive officer, Roche Pharmaceuticals.
“We’re delighted to welcome Alexander back to Genentech as chief executive officer,” said Anderson. “He brings significant global expertise in the delivery of breakthrough medicines and a deep connection to the company culture. I look forward to seeing Genentech’s scientific excellence, employee experience and dedication to patients thrive under his leadership.”
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.